Similar articles

• Decreased kidney function in the elderly: clinical and preclinical, neither benign.

  Coresh J, Astor B. Coresh J, et al. Ann Intern Med. 2006 Aug 15;145(4):299-301. doi: 10.7326/0003-4819-145-4-200608150-00010. Ann Intern Med. 2006. PMID: 16908921 No abstract available.
• Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.

  Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS. Shlipak MG, et al. Ann Intern Med. 2006 Aug 15;145(4):237-46. doi: 10.7326/0003-4819-145-4-200608150-00003. Ann Intern Med. 2006. PMID: 16908914
• Cystatin C and the risk of death.

  Perkins BA, Nelson RG, Krolewski AS. Perkins BA, et al. N Engl J Med. 2005 Aug 25;353(8):842-4; author reply 842-4. N Engl J Med. 2005. PMID: 16124125 No abstract available.
• Cystatin C, kidney function and cardiovascular disease.

  Bökenkamp A, Herget-Rosenthal S, Bökenkamp R. Bökenkamp A, et al. Pediatr Nephrol. 2006 Sep;21(9):1223-30. doi: 10.1007/s00467-006-0192-5. Epub 2006 Jul 13. Pediatr Nephrol. 2006. PMID: 16838182 Review.
• [Cystatin C and cardiovascular risk].

  Taglieri N, Koenig W, Kaski JC. Taglieri N, et al. Ann Biol Clin (Paris). 2010 Sep-Oct;68(5):517-29. doi: 10.1684/abc.2010.0466. Ann Biol Clin (Paris). 2010. PMID: 20870574 Review. French.